Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 10
Submit an article Journal homepage
919
Views
28
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma

Stephanie SasseFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)
,
Achim RotheFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)
,
Helen GoergenFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)
,
Dennis A. EichenauerFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)
,
Andreas LohriMedical University Clinic, Oncology/Hematology, Kantonsspital, Liestal, Switzerland
,
Stephan KreherDepartment of Hematology and Oncology, Virchow-Hospital, Humboldt-University, Berlin, Germany
,
Ulrich JägerDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
,
Christopher BangardDepartment of Radiology
,
Georg KuhnertDepartment of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
,
Boris BöllFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)
,
Bastian von TresckowFirst Department of Internal Medicine
&
Andreas EngertFirst Department of Internal Medicine;The German Hodgkin Study Group (GHSG)Correspondence[email protected]
 show all
Pages 2144-2148 | Received 22 Oct 2012, Accepted 08 Feb 2013, Published online: 27 Mar 2013

References

  • Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791–1799.
  • Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
  • Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074–5080.
  • Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12: 1065–1072.
  • Boll B, Gorgen H, Arndt N, et al. Relapsed Hodgkin lymphoma in elderly patients: a comprehensive analysis from the German Hodgkin Study Group (GHSG). Blood 2011;118(Suppl. 1): Abstract 92.
  • Greaves P, Wilson A, Matthews J, et al. Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. Br J Haematol 2012;157:201–204.
  • Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
  • Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645–652.
  • Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012;11:19–20.
  • Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681–3695.
  • Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation. Blood 2012;120(Suppl. 1): Abstract 2743.
  • Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30: 2190–2196.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
  • Forero-Torres A, Fanale M, Advani R, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012;17: 1073–1080.
  • Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30 + lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre. Haematologica 2012 Oct 12. [Epub ahead of print]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.